Cargando…

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification

Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid clonal diseases with diverse clinical courses, and immune dysregulation plays an important role in the pathogenesis of MDS. However, immune dysregulation is complex and heterogeneous in the development of MDS. Lower-risk MDS (LR-MDS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xiaohuan, Zhu, Xiaofeng, Di, Tianning, Tang, Futian, Guo, Xiaojia, Liu, Yang, Bai, Jun, Li, Yanhong, Li, Lijuan, Zhang, Liansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537682/
https://www.ncbi.nlm.nih.gov/pubmed/36211357
http://dx.doi.org/10.3389/fimmu.2022.994053
_version_ 1784803260386770944
author Peng, Xiaohuan
Zhu, Xiaofeng
Di, Tianning
Tang, Futian
Guo, Xiaojia
Liu, Yang
Bai, Jun
Li, Yanhong
Li, Lijuan
Zhang, Liansheng
author_facet Peng, Xiaohuan
Zhu, Xiaofeng
Di, Tianning
Tang, Futian
Guo, Xiaojia
Liu, Yang
Bai, Jun
Li, Yanhong
Li, Lijuan
Zhang, Liansheng
author_sort Peng, Xiaohuan
collection PubMed
description Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid clonal diseases with diverse clinical courses, and immune dysregulation plays an important role in the pathogenesis of MDS. However, immune dysregulation is complex and heterogeneous in the development of MDS. Lower-risk MDS (LR-MDS) is mainly characterized by immune hyperfunction and increased apoptosis, and the immunosuppressive therapy shows a good response. Instead, higher-risk MDS (HR-MDS) is characterized by immune suppression and immune escape, and the immune activation therapy may improve the survival of HR-MDS. Furthermore, the immune dysregulation of some MDS changes dynamically which is characterized by the coexistence and mutual transformation of immune hyperfunction and immune suppression. Taken together, the authors think that the immune dysregulation in MDS with different risk stratification can be summarized by an advanced philosophical thought “Yin-Yang theory” in ancient China, meaning that the opposing forces may actually be interdependent and interconvertible. Clarifying the mechanism of immune dysregulation in MDS with different risk stratification can provide the new basis for diagnosis and clinical treatment. This review focuses on the manifestations and roles of immune dysregulation in the different risk MDS, and summarizes the latest progress of immunotherapy in MDS.
format Online
Article
Text
id pubmed-9537682
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95376822022-10-08 The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification Peng, Xiaohuan Zhu, Xiaofeng Di, Tianning Tang, Futian Guo, Xiaojia Liu, Yang Bai, Jun Li, Yanhong Li, Lijuan Zhang, Liansheng Front Immunol Immunology Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid clonal diseases with diverse clinical courses, and immune dysregulation plays an important role in the pathogenesis of MDS. However, immune dysregulation is complex and heterogeneous in the development of MDS. Lower-risk MDS (LR-MDS) is mainly characterized by immune hyperfunction and increased apoptosis, and the immunosuppressive therapy shows a good response. Instead, higher-risk MDS (HR-MDS) is characterized by immune suppression and immune escape, and the immune activation therapy may improve the survival of HR-MDS. Furthermore, the immune dysregulation of some MDS changes dynamically which is characterized by the coexistence and mutual transformation of immune hyperfunction and immune suppression. Taken together, the authors think that the immune dysregulation in MDS with different risk stratification can be summarized by an advanced philosophical thought “Yin-Yang theory” in ancient China, meaning that the opposing forces may actually be interdependent and interconvertible. Clarifying the mechanism of immune dysregulation in MDS with different risk stratification can provide the new basis for diagnosis and clinical treatment. This review focuses on the manifestations and roles of immune dysregulation in the different risk MDS, and summarizes the latest progress of immunotherapy in MDS. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9537682/ /pubmed/36211357 http://dx.doi.org/10.3389/fimmu.2022.994053 Text en Copyright © 2022 Peng, Zhu, Di, Tang, Guo, Liu, Bai, Li, Li and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Peng, Xiaohuan
Zhu, Xiaofeng
Di, Tianning
Tang, Futian
Guo, Xiaojia
Liu, Yang
Bai, Jun
Li, Yanhong
Li, Lijuan
Zhang, Liansheng
The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
title The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
title_full The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
title_fullStr The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
title_full_unstemmed The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
title_short The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
title_sort yin-yang of immunity: immune dysregulation in myelodysplastic syndrome with different risk stratification
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537682/
https://www.ncbi.nlm.nih.gov/pubmed/36211357
http://dx.doi.org/10.3389/fimmu.2022.994053
work_keys_str_mv AT pengxiaohuan theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT zhuxiaofeng theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT ditianning theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT tangfutian theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT guoxiaojia theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT liuyang theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT baijun theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT liyanhong theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT lilijuan theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT zhangliansheng theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT pengxiaohuan yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT zhuxiaofeng yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT ditianning yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT tangfutian yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT guoxiaojia yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT liuyang yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT baijun yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT liyanhong yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT lilijuan yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification
AT zhangliansheng yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification